Last reviewed · How we verify
Ebola Vaccine - low dose
At a glance
| Generic name | Ebola Vaccine - low dose |
|---|---|
| Also known as | Ebola Zaire Vaccine (2.5 x 10^4 pfu) |
| Sponsor | Auro Vaccines LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of a New Vaccine Against Two Types of Ebola (PHASE1)
- A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo (PHASE1)
- Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults (PHASE1)
- A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. (PHASE1)
- A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland (PHASE1, PHASE2)
- A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization (PHASE1)
- A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. (PHASE1)
- A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ebola Vaccine - low dose CI brief — competitive landscape report
- Ebola Vaccine - low dose updates RSS · CI watch RSS
- Auro Vaccines LLC portfolio CI